The large-cap S&P 500
Index and the technology-heavy Nasdaq Composite Index reached new intraday and
closing highs this week, while the smaller-cap stocks remained some distance
from their late-2018 peaks. Within the SPDR S&P 500 ETF (SPY), health care shares
outperformed, helped by earnings beats from Merck (MRK) and Pfizer (PFE). Energy shares lagged
as oil prices fell after some oversupply concerns. As to improved sentiment on
Wall Street, the Cboe Volatility Index (VIX), the so-called fear gauge, touched
a four-month low – another glimpse of good news.
ETFG Quant Movers –
Those ETFs who have had the largest weekly change in their respective, overall
ETFG Quant ratings.
ETFG Quant Winners: The top five gainers in the ETFG Quant Total Score
were First Trust Nasdaq Food & Beverage ETF (FTXG),
KraneShares CICC China Leaders 100 Index ETF (KFYP),
Schwab Fundamental U.S. Large Company Index (FNDX), iShares
Russell Mid-Cap ETF (IWR) and Vanguard Small-Cap ETF (VB)
respectively. Each ETP added well over 15% to their score as behavioral scores
and global factors came into play.
ETFG Quant Losers: Honorable mentions in the loser category were WBI
Power Factor High Dividend ETF (WBIY), Global X US Preferred ETF (PFFD),
VanEck Vectors Pharmaceutical ETF (PPH),
Consumer Staples Select Sector SPDR Fund (XLP) and
JPMorgan Diversified Return Emerging Markets Equity ETF (JPEM). The
causes can be traced to fundamental and behavioral factors dipping slightly
impacting the respective total ETFG Quant scores.
ETFG Weekly Select List -
The five most highly rated ETFs per Sector, Geographic Region and Strategy as
ranked by the ETFG Quant model.
Considering the sector’s
success, we’d like to highlight the top ETFs within the health care sector in
this week’s Select List. iShares Nasdaq Biotechnology ETF (IBB) held onto the 1st
place position followed by iShares Global Healthcare ETF (IXJ) in 2nd and
VanEck Vectors Biotech ETF (BBH)
in 3rd place. Followed by newcomers to this week’s select list, SPDR
S&P Pharmaceuticals ETF (XPH)
and Invesco Dynamic Pharmaceuticals ETF (PJP) claiming the 4th
and 5th spot respectively.
Thanks for reading ETF
Global Perspectives!
ETFG 21 Day Free
Trial: https://www.etfg.com/signup/quick
_______________________________________________________
Assumptions, opinions and estimates constitute
our judgment as of the date of this material and are subject to change without
notice. ETF Global LLC (“ETFG”) and its
affiliates and any third-party providers, as well as their directors, officers,
shareholders, employees or agents (collectively ETFG Parties) do not guarantee
the accuracy, completeness, adequacy or timeliness of any information,
including ratings and rankings and are not responsible for errors and omissions
or for the results obtained from the use of such information and ETFG Parties
shall have no liability for any errors, omissions, or interruptions therein,
regardless of the cause, or for the results obtained from the use of such
information. ETFG PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES,
INCLUDING, BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR
FITNESS FOR A PARTICULAR PURPOSE OR USE.
In no event shall ETFG Parties be liable to any party for any direct,
indirect, incidental, exemplary, compensatory, punitive, special or
consequential damages, costs, expenses, legal fees, or losses (including,
without limitation, lost income or lost profits and opportunity costs) in
connection with any use of the information contained in this document even if
advised of the possibility of such damages.
ETFG ratings and rankings are statements of
opinion as of the date they are expressed and not statements of fact or
recommendations to purchase, hold, or sell any securities or to make any
investment decisions. ETFG ratings and rankings should not be relied on when
making any investment or other business decision. ETFG’s opinions and analyses do not address
the suitability of any security. ETFG
does not act as a fiduciary or an investment advisor. While ETFG has obtained information from sources
they believe to be reliable, ETFG does not perform an audit or undertake any
duty of due diligence or independent verification of any information it
receives.
This material is not intended as an offer or
solicitation for the purchase or sale of any security or other financial
instrument. Securities, financial instruments or strategies mentioned herein
may not be suitable for all investors.
Any opinions expressed herein are given in good faith, are subject to
change without notice, and are only correct as of the stated date of their
issue. Prices, values, or income from
any securities or investments mentioned in this report may fall against the
interests of the investor and the investor may get back less than the amount
invested. Where an investment is
described as being likely to yield income, please note that the amount of income
that the investor will receive from such an investment may fluctuate. Where an investment or security is
denominated in a different currency to the investor's currency of reference,
changes in rates of exchange may have an adverse effect on the value, price or
income.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.